胸腺肽a1联合化疗对晚期卵巢癌患者细胞免疫功能的影响
|
摘要
目的探讨胸腺肽α1联合化疗对晚期卵巢癌患者细胞免疫功能的影响。方法方便选取2013年6月—2016年12月在厦门市中医院肿瘤科收治的52例卵巢癌患者随机分为两组,对照组采用紫杉醇+顺铂常规化疗,观察组在对照组治疗基础上加用胸腺肽α1。比较两组疗效、不良反应,化疗前后血清CRP及外周血NK细胞、T淋巴细胞亚群变化。结果两组总有效率分别为73.1%和65.4%,差异有统计学意义(P>0.05);但观察组骨髓抑制严重不良反应发生率低于对照组34.6%vs 69.2%,差异有统计学意义(P<0.05)。化疗后两组CRP分别为(18.64±9.23)和(29.71±9.55),均低于化疗前,且观察组低于对照组;而CD3~+、CD4~+、CD4~+/CD8~+及NK细胞活性分别为(76.98±4.63)%,(37.45±2.60)%,(1.66±0.10),(16.86±2.40)%,均高于化疗前,且观察组明显高于对照组。结论胸腺肽α1联合化疗可增强机体细胞免疫功能,减轻化疗不良反应。
Objective This paper tries to observe the effect of thymosin α1 combined with chemotherapy on cellular immune function in patients with advanced ovarian cancer. Methods A total of 52 patients with ovarian cancer hospitalized in oncology department in this hospital from June 2013 to December 2016 were convenient selected and randomly divided into two groups. The control group received conventional chemotherapy with paclitaxel plus cisplatin. The observation group was treated with thymosin α1 on the basis of the control group. The effects and adverse reactions of the two groups were compared, and the changes of serum CRP, NK cells and T lymphocyte subsets in peripheral blood before and after chemotherapy were compared. Results The total effective rate was 73.1% and 65.4% in both groups the difference was statistically significant(P>0.05). However, the incidence of serious adverse reactions in the observation group was lower than that in the control group(34.6% vs 69.2%),the difference with significant difference(P <0.05). The CRP levels of two groups after chemotherapy were(18.64±9.23) and(29.71±9.55), respectively, which were lower than those before chemotherapy and lower than those of the control group. The activities of CD3~+, CD4~+, CD4~+/CD8~+ and NK cells were(76.98±4.63)% and(37.45±2.60)%,(1.66±0.10),(16.86±2.40)%, respectively, which were higher than before chemotherapy, and the observation group was significantly higher than the control group. Conclusion Thymosin α1 combined with chemotherapy can enhance the body's cellular immune function, reduce chemotherapy adverse reactions.
Objective This paper tries to observe the effect of thymosin α1 combined with chemotherapy on cellular immune function in patients with advanced ovarian cancer. Methods A total of 52 patients with ovarian cancer hospitalized in oncology department in this hospital from June 2013 to December 2016 were convenient selected and randomly divided into two groups. The control group received conventional chemotherapy with paclitaxel plus cisplatin. The observation group was treated with thymosin α1 on the basis of the control group. The effects and adverse reactions of the two groups were compared, and the changes of serum CRP, NK cells and T lymphocyte subsets in peripheral blood before and after chemotherapy were compared. Results The total effective rate was 73.1% and 65.4% in both groups the difference was statistically significant(P>0.05). However, the incidence of serious adverse reactions in the observation group was lower than that in the control group(34.6% vs 69.2%),the difference with significant difference(P <0.05). The CRP levels of two groups after chemotherapy were(18.64±9.23) and(29.71±9.55), respectively, which were lower than those before chemotherapy and lower than those of the control group. The activities of CD3~+, CD4~+, CD4~+/CD8~+ and NK cells were(76.98±4.63)% and(37.45±2.60)%,(1.66±0.10),(16.86±2.40)%, respectively, which were higher than before chemotherapy, and the observation group was significantly higher than the control group. Conclusion Thymosin α1 combined with chemotherapy can enhance the body's cellular immune function, reduce chemotherapy adverse reactions.
引文
[1]冯勤梅,吴霞,狄文.卵巢癌患者化疗前后免疫细胞格局变化[J].现代免疫学,2010,30(4):337-341.
[2]杨学宁,吴一龙.实体瘤治疗疗效评价标准[J].循证医学,2004,4(2):85-111.
[3]曹泽毅.妇科常见肿瘤诊治指南[M].北京:人民卫生出版社,2013:129-133.
[4]郑晓,封巍,刘冠,等.日达仙联合放化疗治疗非小细胞肺癌疗效分析[J].浙江医学,2007,29(10):1059-1061.
[5]王英禹,张瑞,周勇安,等.非小细胞肺癌术后化疗中应用胸腺肽的近期临床观察[J].中国误诊学杂志,2007,7(3):416-418.
[6]程峰.卵巢癌FIGO分期与C反应蛋白相关性分析[J].中外医学研究,2015,13(24):18-19.
[7]Lampl B,Leebmann H,Mayr M,etal.Rare diaphragmatic complications following cytoreductive surgery and HIPEC:report of twocases[J].Surg Today,2014,44(2):383-386.
[8]Aoyagi T,Terracina KP,Raza A,et al.Current treatment options for colon cancer peritoneal carcinomatosis[J].World J Gastroenterol,2014,20(35):12493-12500.
[9]汪正广,齐东江,李嘉嘉,等.中晚期胃癌患者术后化疗联合黄芪颗粒治疗对生活质量及免疫功能的影响[J].安徽医科大学学报,2014,49(12):1771-1774.
[10]冯访梅,朱筱勇,董丽钧.腹腔低渗热灌注联合FOLFOX6化疗对结肠癌根治术后外周血T淋巴细胞亚群和NK细胞的影响[J].临床和实验医学杂志,2016,15(23):2349-2353.
[2]杨学宁,吴一龙.实体瘤治疗疗效评价标准[J].循证医学,2004,4(2):85-111.
[3]曹泽毅.妇科常见肿瘤诊治指南[M].北京:人民卫生出版社,2013:129-133.
[4]郑晓,封巍,刘冠,等.日达仙联合放化疗治疗非小细胞肺癌疗效分析[J].浙江医学,2007,29(10):1059-1061.
[5]王英禹,张瑞,周勇安,等.非小细胞肺癌术后化疗中应用胸腺肽的近期临床观察[J].中国误诊学杂志,2007,7(3):416-418.
[6]程峰.卵巢癌FIGO分期与C反应蛋白相关性分析[J].中外医学研究,2015,13(24):18-19.
[7]Lampl B,Leebmann H,Mayr M,etal.Rare diaphragmatic complications following cytoreductive surgery and HIPEC:report of twocases[J].Surg Today,2014,44(2):383-386.
[8]Aoyagi T,Terracina KP,Raza A,et al.Current treatment options for colon cancer peritoneal carcinomatosis[J].World J Gastroenterol,2014,20(35):12493-12500.
[9]汪正广,齐东江,李嘉嘉,等.中晚期胃癌患者术后化疗联合黄芪颗粒治疗对生活质量及免疫功能的影响[J].安徽医科大学学报,2014,49(12):1771-1774.
[10]冯访梅,朱筱勇,董丽钧.腹腔低渗热灌注联合FOLFOX6化疗对结肠癌根治术后外周血T淋巴细胞亚群和NK细胞的影响[J].临床和实验医学杂志,2016,15(23):2349-2353.